Pipeline — registered trials by phase
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Veeva Systems is lead sponsor; 0 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 10-Q2026-08-27Quarterly report
- 8-K2026-08-26Current report (material event)
- 8-K2026-08-20Current report (material event)
- SCHEDULE 13G2026-07-31SCHEDULE 13G
- SCHEDULE 13G/A2026-07-30SCHEDULE 13G/A
- 8-K2026-06-18Current report (material event)
- 10-Q2026-06-05Quarterly report
- 8-K2026-06-03Current report (material event)
- ARS2026-05-04Annual report to holders
- DEFA14A2026-05-04DEFA14A
- DEF 14A2026-05-04Proxy statement
- 8-K2026-04-20Current report (material event)
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- S-82026-03-20Employee stock plan
- 10-K2026-03-20Annual report
- 8-K2026-03-04Current report (material event)
- 8-K2026-01-05Current report (material event)
- 8-K2025-12-11Current report (material event)
- 10-Q2025-11-21Quarterly report
- 8-K2025-11-20Current report (material event)
- 8-K2025-11-18Current report (material event)
- SCHEDULE 13G/A2025-10-31SCHEDULE 13G/A
- 10-Q2025-08-29Quarterly report
- 8-K2025-08-27Current report (material event)
- 8-K2025-08-18Current report (material event)
- 8-K2025-06-23Current report (material event)
- DEFA14A2025-06-04DEFA14A
- 10-Q2025-06-02Quarterly report
- 8-K2025-05-28Current report (material event)
- DEFA14A2025-05-13DEFA14A
- ARS2025-05-05Annual report to holders
- DEFA14A2025-05-05DEFA14A
- DEF 14A2025-05-05Proxy statement
- S-82025-03-24Employee stock plan
- 10-K2025-03-24Annual report
- 8-K2025-03-12Current report (material event)
- 8-K2025-03-05Current report (material event)
- 10-Q2024-12-09Quarterly report
- 8-K2024-12-05Current report (material event)
- 8-K2024-11-08Current report (material event)
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.